Delivery Order SPE2DB20D2014-SPE2DB25FC45A
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $14,452.05 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of AVEED 750 mg/3 mL vials. The contract represents a firm fixed price delivery order with an ultimate completion date of August 20, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established capability to meet...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of AVEED 750 MG/3 ML vials. The contract, valued at $23,123.28, carries a firm fixed price and requires completion by June 23, 2025. This is a non-set-aside delivery order issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued at $999,999,999 and...
- The Defense Logistics Agency awarded a delivery order valued at $19,269.40 to AmerisourceBergen Drug Corp for AVEED 750 mg/3 mL vials on July 16, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AVEED (testosterone undecanoate) is a prescription testosterone replacement therapy indicated for...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,853.88 for AVEED 750 mg/3 mL vials on September 15, 2025, with an ultimate completion date of October 6, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AVEED (testosterone undecanoate) is a prescription testosterone replacement therapy indicated for treating low...
- The Defense Logistics Agency awarded a $4,817.35 delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for AVEED 750 mg/3 mL vials. This competitively awarded contract, with an ultimate completion date of August 27, 2025, represents a firm fixed-price transaction with no set-aside designation. The product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of AVEED 750 mg/3 mL vials with a ceiling value of $10,153.60 and a firm fixed price. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of December 23, 2025. The award will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AVEED is a pharmaceutical product used in testosterone replacement...
- The Defense Logistics Agency awarded a $1,926.94 delivery order to AmerisourceBergen Drug Corp for AVEED 750 mg/3 ml vials on October 22, 2025, with an ultimate completion date of November 13, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $44,319.62 to AmerisourceBergen Drug Corp for AVEED 750 mg/3 mL vials on August 7, 2025, with completion targeted for August 28, 2025. This firm fixed-price delivery order, which was not set aside for small business, represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's distribution center in...
- The Defense Logistics Agency awarded a $34,684.92 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of AVEED 750 MG/3 ML vials. The contract is competitively awarded with no set-aside designation and carries a firm fixed price structure with an ultimate completion date of September 5, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of AVEED 750 MG/3 ML vials. This competitive, firm fixed-price delivery order, valued at $2,890.41, was executed on August 22, 2025, with an ultimate completion date of September 15, 2025. The products will be performed and delivered from AmerisourceBergen's location in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC45ADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $14,452.05 to AmerisourceBergen Drug Corp for AVEED 750 mg/3 mL vials on July 14, 2025, with completion by August 4, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. AVEED is a testosterone replacement therapy product used in the treatment of hypogonadism, reflecting the ongoing pharmaceutical supply needs of military and federal healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime pharmaceutical vendor contract enables AmerisourceBergen to supply a comprehensive range of medications, vaccines, and medical supplies to support military healthcare programs globally, including the Defense Health Agency and U.S. Coast Guard. The company's position as a critical pharmaceutical distributor is further reinforced by DLA's broader strategy to establish Pharmaceutical Prime Vendor Global Program Generation V contracts, which are expected to involve multiple regional awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.5k | 7/14/25 |